Should Dapagliflozin Be Started in a 60-Year-Old with Hypertension and Prediabetes?
No, dapagliflozin should not be routinely initiated in a 60-year-old patient with hypertension and only prediabetes, unless there is established cardiovascular disease, heart failure, or chronic kidney disease with albuminuria. The current evidence and guidelines do not support SGLT2 inhibitor use solely for hypertension management or prediabetes prevention in patients without established cardiorenal disease 1.
Risk Stratification Is Critical
The decision hinges entirely on whether this patient has additional cardiovascular or renal risk factors beyond hypertension and prediabetes:
Lower Risk Profile (Hypertension + Prediabetes Only)
If the patient has three or fewer cardiovascular risk factors and no established cardiovascular disease or chronic kidney disease, current guidelines provide a weak recommendation against initiating SGLT2 inhibitors like dapagliflozin 2.
The 2024 ESC hypertension guidelines recommend first-line treatment with thiazide/thiazide-like diuretics, ACE inhibitors/ARBs, or calcium channel blockers—not SGLT2 inhibitors—for blood pressure control 1.
While small trials show dapagliflozin modestly reduces blood pressure in prediabetes (systolic BP reduction of 10.4 mmHg at 12 weeks), these were exploratory studies not powered for cardiovascular outcomes 3, 4, 5.
Higher Risk Profile (Additional Cardiorenal Disease)
If the patient has established cardiovascular disease (prior MI, stroke, peripheral artery disease), heart failure, or chronic kidney disease with eGFR 25-75 mL/min/1.73 m² and albuminuria (UACR ≥200 mg/g), then dapagliflozin receives a strong recommendation 1, 2.
The DAPA-CKD trial demonstrated a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or cardiovascular/renal death (HR 0.61,95% CI 0.51-0.72), with benefits independent of diabetes status 1, 6.
For patients with more than three cardiovascular risk factors but without established disease, guidelines provide a weak recommendation in favor of SGLT2 inhibitors 2.
Prediabetes Alone Is Not an Indication
Although dapagliflozin reduces progression to type 2 diabetes in prediabetes patients (10.1% vs 13.1% with placebo over 1 year in post-MI patients), this benefit alone does not justify initiation without established cardiorenal disease 7.
The 2020 ADA Standards of Care recommend metformin—not SGLT2 inhibitors—as the pharmacologic option for diabetes prevention in high-risk prediabetes patients (those with BMI ≥35 kg/m² or history of gestational diabetes) 1.
Small trials showing metabolic benefits (weight loss of 1-4 kg, improved insulin sensitivity) in prediabetes are insufficient to support routine use without cardiovascular outcome data in this population 8, 9.
Hypertension Management Takes Priority
The 2024 ESC guidelines recommend targeting systolic BP of 120-129 mmHg using combination therapy with a RAS blocker (ACE inhibitor or ARB) plus a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic 1.
Beta-blockers are recommended only when there are compelling indications (angina, post-MI, heart failure, or heart rate control) 1.
Dapagliflozin's blood pressure-lowering effect (3-4 mmHg systolic reduction) is modest compared to standard antihypertensives and does not justify its use solely for hypertension 5.
Critical Assessment Needed Before Considering Dapagliflozin
To determine if this patient might benefit from dapagliflozin, systematically evaluate:
Cardiovascular disease status: Prior MI, stroke, coronary revascularization, peripheral artery disease, or documented atherosclerosis 1, 2.
Heart failure: Any history of heart failure with reduced or preserved ejection fraction, or elevated natriuretic peptides 1.
Kidney function and albuminuria: Check eGFR and urine albumin-to-creatinine ratio; dapagliflozin is indicated if eGFR 25-75 mL/min/1.73 m² with UACR ≥200 mg/g 1, 6.
Cardiovascular risk factor burden: Count total risk factors including age >55 years (men) or >60 years (women), smoking, dyslipidemia, family history of premature CVD, and obesity 2.
Common Pitfall to Avoid
Do not initiate dapagliflozin based solely on modest blood pressure reduction or prediabetes prevention without established cardiorenal disease, as this represents off-label use not supported by outcome trials demonstrating mortality or morbidity benefit in this population 1, 2.
The FDA label explicitly states that dapagliflozin for glycemic control "is not recommended when eGFR is less than 45 mL/min/1.73 m² in patients without established CV disease or CV risk factors" 10.
Alternative Approach for This Patient
Optimize lifestyle interventions: Intensive lifestyle modification (7% weight loss, 150 minutes/week moderate exercise) reduces diabetes risk by 58% in prediabetes—superior to any medication 1.
Initiate guideline-directed antihypertensive therapy: Start combination therapy with ACE inhibitor/ARB plus calcium channel blocker or thiazide diuretic to achieve BP target of 120-129/70-79 mmHg 1.
Consider metformin for diabetes prevention: If BMI ≥35 kg/m² or history of gestational diabetes, metformin 850 mg twice daily reduces diabetes risk by 31% and is the evidence-based pharmacologic choice 1.
Reassess in 3-6 months: If cardiovascular disease or chronic kidney disease develops, or if cardiovascular risk stratification reveals higher risk, then reconsider dapagliflozin initiation 2.